It’s a nothing burger. Amarin has sales projections based on no generics until 2029, billions of dollars per year down the road they say. Should the judge hold that against them? The generics are planning on making Vascepa, that’s why Amarin is suing them. So they are projecting sales like Amarin, no different, if you read Amarin filings the risks are there including generics suit, same would be for Hikma.
Market Data 
Markets 
AI
